DKSH

Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021

Retrieved on: 
Monday, August 29, 2022
Partnership, Osteoporosis, COVID-19, Sustainability, Teva Pharmaceuticals, Cancer, CEO, Heat, Degenerative disease, NASDAQ, Respiratory disease, Biosimilar, DKSH, Disclosure, Ethics, Forward-looking statement, SEC, Goal, GLOBE, Stada Arzneimittel, Board of directors, Company, ESG, Communication, Terminology, Director, Marketing, Patient, Renewable energy, Management, EU

Information related to sustainability can now be found on a dedicated ESG portal which is part of the Companys website www.alvotech.com/corporate sustainability.

Key Points: 
  • Information related to sustainability can now be found on a dedicated ESG portal which is part of the Companys website www.alvotech.com/corporate sustainability.
  • Alvotechs corporate headquarters, purpose-built manufacturing facility and a large part of the Companys R&D operations are located in Reykjavik, Iceland.
  • Todays disclosure is the first step in our journey to improve our stakeholder engagement and demonstrate our commitment to corporate sustainability, added Mark Levick, CEO of Alvotech.
  • As part of the sustainability strategy, Alvotech has designated Ming Li, Chief Strategy Officer for the company as its Head of Sustainability.

Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Retrieved on: 
Thursday, August 25, 2022
COVID-19, CEO, Safety, Pharmacokinetics, Respiratory disease, Man, Denosumab, Volunteering, GLOBE, Adult, Risk, Patient, Cancer, Biosimilar, SEC, Fracture, Communication, Bone loss, Terminology, Woman, Trial of the century, Partnership, Osteoporosis, BMD, Teva Pharmaceuticals, Autoimmune disease, NASDAQ, DKSH, Adalimumab, Private Securities Litigation Reform Act, Marketing, RANK, Degenerative disease, Goal, Stada Arzneimittel, Bone disease, Forward-looking statement, Generic drug, EU

In 2021, combined net revenues worldwide from sales of Prolia and Xgeva were nearly US$5.3 billion.

Key Points: 
  • In 2021, combined net revenues worldwide from sales of Prolia and Xgeva were nearly US$5.3 billion.
  • We are proud to be able to initiate the confirmatory patient study for AVT03, adding another important milestone in the development of our biosimilars portfolio.
  • A biosimilar to Humira (adalimumab) is already approved in Europe (Hukyndra) and Canada (Simlandi), and three biosimilar candidates including AVT03 have entered or completed confirmatory patient studies.
  • AVT03 is a human monoclonal antibody and a biosimilar candidate to Prolia and Xgeva (denosumab).

Alvotech to Participate in Two Upcoming Investor Conferences in September 2022

Retrieved on: 
Wednesday, August 24, 2022
Partnership, Osteoporosis, Teva Pharmaceuticals, Cancer, Degenerative disease, NASDAQ, Respiratory disease, Biosimilar, Morgan, DKSH, NEW, GLOBE, Stada Arzneimittel, Conference, Investor, Webcast, Patient, Pharmaceutical industry, EU, News

REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in two upcoming investor conferences in September 2022.

Key Points: 
  • REYKJAVIK, Iceland and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in two upcoming investor conferences in September 2022.
  • Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.
  • Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners.
  • None of the information on the Alvotech website shall be deemed part of this press release.

Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022

Retrieved on: 
Monday, August 15, 2022
Teva Pharmaceuticals, GLOBE, DKSH, Cancer, Patient, Biosimilar, Partnership, NASDAQ, Degenerative disease, Respiratory disease, Webcast, Investor, Stada Arzneimittel, Osteoporosis, News, EU

Following the release, Alvotech will conduct a business update conference call and live webcast on Thursday, September 1, 2022, at 8:00 am ET (12:00 pm GMT).

Key Points: 
  • Following the release, Alvotech will conduct a business update conference call and live webcast on Thursday, September 1, 2022, at 8:00 am ET (12:00 pm GMT).
  • In order to participate in the conference call, please register in advance following this link to obtain a local or toll-free phone number and your personal pin.
  • Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.
  • None of the information on the Alvotech website shall be deemed part of this press release.

Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

Retrieved on: 
Friday, August 12, 2022
Teva Pharmaceuticals, GLOBE, DKSH, SEC, Cancer, Board, Communication, Marketing, Patient, FTSE Global Equity Index Series, Person, Degenerative disease, Board of directors, Regulation, Terminology, EC, Sale, FTSE, Transparency Directive, Nasdaq First North, Partnership, Bone disease, Nasdaq, Osteoporosis, Forward-looking statement, Compliance, European, COVID-19, Jos Main Market, Respiratory disease, Goal, ISK, Stada Arzneimittel, Biosimilar, NASDAQ, Luxembourg Commission, Fine chemical, Security (finance), Pharmaceutical industry, EU, Securities Act of 1933, USD

A Main Market listing can increase a companys visibility and may result in inclusion in Icelandic and international indexes.

Key Points: 
  • A Main Market listing can increase a companys visibility and may result in inclusion in Icelandic and international indexes.
  • Alvotechs shares are currently listed on the Nasdaq Stock Market in the U.S. and on the Nasdaq First North Growth Market under the ticker symbol ALVO.
  • Alvotechs shares were admitted to trading in the U.S. on June 16, 2022 and in Iceland on June 23, 2022 .
  • The Nasdaq First North Growth Market is a multilateral trading facility (MTF) governed by a less extensive rulebook than the Main Market.

Stilla Technologies Solidifies Leadership in EMEA, Expands Footprint in APAC

Retrieved on: 
Tuesday, August 2, 2022
General Health, Health, Science, Other Science, Research, Food, Genomics, Industry, Twitter, DKSH, Caliper Life Sciences, CEO, Research, Infection, Multimedia, EMEA, Proteomics, Cancer, Technology, FUJIFILM, ITS, YouTube, LinkedIn, PCR, PerkinElmer, Management, Sergeant, Stilla, Eppendorf

Stilla Technologies, the multiplex digital PCR company, announces the addition of Yvan Sergeant to serve in the capacity of Vice President/General Manager for the EMEA region.

Key Points: 
  • Stilla Technologies, the multiplex digital PCR company, announces the addition of Yvan Sergeant to serve in the capacity of Vice President/General Manager for the EMEA region.
  • Yvan held prior leadership positions at PerkinElmer, Caliper Life Sciences, and Trinean, and comes to Stilla from Quanterix where he served as VP/GM, Europe.
  • Along with the addition of Sergeant, Stilla Technologies also announces several new distribution partnerships in Asia.
  • With today's addition of six strategic partners in APAC, Stilla substantially increases its global market presence, and strengthens its ability to serve customers globally, notes Philippe Mourere, President and CEO of Stilla Technologies.

The Future of Work is Here for Chief Audit Executives, According to Protiviti's "Internal Auditing Around the World" Report

Retrieved on: 
Thursday, July 14, 2022
Technology, Multimedia, The Future of Work and Death, Solution, Risk, Work, Commerzbank, Government, RHI, AstraZeneca, CAES, SoFi, DKSH, Bacardi, Internal, NYSE, Mission statement, Audit, Protiviti

MENLO PARK, Calif., July 14, 2022 /PRNewswire/ -- In the 18th edition of its Internal Auditing Around the World® profile series, global consulting firm Protiviti shares insights from its interviews with chief audit executives (CAEs) from some of the world's well-known companies about what they have learned from the pandemic and what the future of the internal audit profession looks like now. The report underscores the growing importance of the internal audit function to the business during a time of intense disruption and highlights the innovative ways in which many companies are developing the role of the internal audit professional.

Key Points: 
  • The companies profiled in the study, titled "The Future of Work is Here," represent a mix of countries and industries.
  • The experiences of nine corporate internal audit leaders are presented as case studies in Protiviti's report.
  • To access a complimentary copy and view past editions of Internal Auditing Around the World, please visit here .
  • The firm also works with smaller, growing companies, including those looking to go public, as well as with government agencies.

DKSH Publishes Fifth Sustainability Report and Achieves 2025 Climate Target Ahead of Time

Retrieved on: 
Thursday, July 7, 2022
People, SGS, E-commerce, GHG, CEO, Technology, Sustainability reporting, United Nations Global Compact, Marketing, ISAE, Climate change, Growth, Final good, DKSH, Partner, Greenhouse gas, SIX Swiss Exchange, GRI, CHF, Global, Renewable energy

DKSH reduced its total Scope 1 and 2 emissions by 40% in 2021, ahead of the 35% target until 2025.

Key Points: 
  • DKSH reduced its total Scope 1 and 2 emissions by 40% in 2021, ahead of the 35% target until 2025.
  • With this, DKSH has announced a new target to reduce 65% of its own greenhouse gas emissions by 2025.
  • .Zurich, July 7, 2022 DKSH continued to make good progress on its sustainability journey in 2021, translating its company value of Sustainability into tangible actions.
  • DKSH has reduced its own greenhouse gas (GHG) emissions by 40% from its baseline of 2020, ahead of its reduction target of 35% by 2025.

DKSH Expands its European Food Ingredients Business by Acquiring Georg Breuer GmbH

Retrieved on: 
Monday, July 4, 2022
GBFI, E-commerce, Acquisition, Research, Technology, Small Business Saturday, United Nations Global Compact, Marketing, Growth, Final good, DKSH, Food, SIX Swiss Exchange, Volvo Business Units, CHF, Food industry, Fine chemical

DKSH Business Unit Performance Materials has signed an agreement to acquire Georg Breuer GmbH (GBFI), a German distributor of plant-based ingredients for the food industry.

Key Points: 
  • DKSH Business Unit Performance Materials has signed an agreement to acquire Georg Breuer GmbH (GBFI), a German distributor of plant-based ingredients for the food industry.
  • With this acquisition DKSH expands its food ingredients business in Europe, particularly in the promising plant-based healthy foods segment.
  • Georg Breuer, GBFIs CEO, commented: During the past 30 years we have built a successful company for plant-based food ingredients.
  • The DKSH Business Unit Performance Materials distributes specialty chemicals and ingredients for food, pharmaceutical, personal care, and various industrial applications.

DKSH Performance Materials Strengthens its Life Sciences Capabilities by Acquiring Refarmed Group

Retrieved on: 
Monday, June 27, 2022
Active ingredient, E-commerce, Acquisition, Technology, Small Business Saturday, United Nations Global Compact, Marketing, Growth, Pharma, API, Final good, Food, SIX Swiss Exchange, FDF, List of life sciences, Volvo Business Units, CHF, Form, Fine chemical, DKSH

With this transaction, DKSH Performance Materials significantly expands its capabilities in Active Pharmaceutical Ingredients (APIs) and strengthens its position as a leading Life Sciences distributor.

Key Points: 
  • With this transaction, DKSH Performance Materials significantly expands its capabilities in Active Pharmaceutical Ingredients (APIs) and strengthens its position as a leading Life Sciences distributor.
  • Refarmed Group provides Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) for generic drug manufacturers.
  • Thomas Sul and Natale Capri, Co-Heads Business Unit Performance Materials at DKSH, jointly added: We are excited to strengthen our capabilities in Life Sciences by teaming up with a trusted player with strong expertise.
  • The DKSH Business Unit Performance Materials distributes specialty chemicals and ingredients for food, pharmaceutical, personal care, and various industrial applications.